

Form PTO-1449 (modified)		Atty. Docket No.: <b>INGN:097US</b>	Serial No.: <b>10/017,472</b>
List of Patents and Publications for Applicant's		Applicant: <b>Sunil Chada <i>et al.</i></b>	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Filing Date: <b>December 7, 2001</b>	Group: <b>1633</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C272	Chada <i>et al.</i> , "mda-7/IL24 Kills Pancreatic Cancer Cells by Inhibition of the Wnt/PI3K Signaling Pathways: Identification of IL-20 Receptor-Mediated Bystander Activity against Pancreatic Cancer," <i>Mol. Ther.</i> , 11(5):724-733, 2005.
	C273	Inoue <i>et al.</i> , "Inhibition of Src Kinase Activity by Ad-mda7 Suppresses Vascular Endothelial Growth Factor Expression in Prostate Carcinoma Cells," <i>Mol. Ther.</i> , 12:707-715, 2005.
	C274	Mellinghoff <i>et al.</i> , "Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors," <i>New Eng. J. Med.</i> , 353:2012-2024, 2006.
	C275	Normano <i>et al.</i> , "The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib," <i>J. Cell Physiol.</i> , 207:420-427, 2006.
	C276	Sutter <i>et al.</i> , "Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer," <i>Int. J. Cancer</i> , 118:1814-1822, 2006.
	C277	Xia <i>et al.</i> , "A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer," <i>Proc. Natl. Acad. Sci. USA</i> , 103:7795-7800, 2006.

25784843.1

EXAMINER: /Q. Janice Li/ (03/06/2008)

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /qjl/